Detalles de la búsqueda
1.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Gynecol Oncol
; 183: 61-67, 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38518529
2.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37355448
3.
Synchronous Endometrial and Ovarian Carcinomas: Pathologic and Molecular Analysis Highlights the Monoclonal Origin of the Lesions.
Int J Gynecol Pathol
; 2023 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37922918
4.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Gynecol Oncol
; 164(3): 505-513, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35063281
5.
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Support Care Cancer
; 28(5): 2435-2442, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048043
6.
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study.
Breast J
; 26(7): 1296-1301, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31837103
7.
Immune characterization of breast cancer metastases: prognostic implications.
Breast Cancer Res
; 20(1): 62, 2018 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29929548
8.
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.
J Neurooncol
; 131(2): 369-376, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27853958
9.
Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia.
Blood
; 121(19): 3843-54, S1, 2013 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23515927
10.
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy.
NPJ Breast Cancer
; 7(1): 101, 2021 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34341356
11.
Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center.
Front Oncol
; 10: 608783, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33381461
12.
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Eur J Cancer
; 136: 7-15, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32622323
13.
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases.
ESMO Open
; 5(5): e000843, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33020219
14.
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center.
J Womens Health (Larchmt)
; 28(4): 544-550, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29963941
15.
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease.
Front Oncol
; 9: 452, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31245286
16.
Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.
Anticancer Res
; 36(12): 6541-6546, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27919980
17.
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis.
Breast
; 47: 77-84, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31357134
Resultados
1 -
17
de 17
1
Próxima >
>>